Ticker >

Kilitch Drugs(India) share price

Kilitch Drugs (India) Ltd.

NSE: KILITCH BSE: 524500 SECTOR: Pharmaceuticals & Drugs  12k   15   1

249.00
0 0
NSE: 29 Sep 03:15 PM

Price Summary

Today's High

₹ 249

Today's Low

₹ 248

52 Week High

₹ 250

52 Week Low

₹ 125

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

400.45 Cr.

Enterprise Value

418.33 Cr.

No. of Shares

1.61 Cr.

P/E

23.71

P/B

1.92

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  129.94

CASH

2.45 Cr.

DEBT

20.33 Cr.

Promoter Holding

68.25 %

EPS (TTM)

₹  10.5

Sales Growth

50.19%

ROE

6.23 %

ROCE

7.83%

Profit Growth

71.03 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year50.19%
3 Year2.94%
5 Year30.17%

Profit Growth

1 Year71.03%
3 Year-10.67%
5 Year211.06%

ROE%

1 Year6.23%
3 Year4.38%
5 Year5.77%

ROCE %

1 Year7.83%
3 Year5.51%
5 Year7.27%

Debt/Equity

0.1161

Price to Cash Flow

76.94

Interest Cover Ratio

18.5175449628977

CFO/PAT (5 Yr. Avg.)

0.587007225069709

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2023 68.25 0
Mar 2023 68.25 0
Dec 2022 68.25 0
Sep 2022 68.25 0
Jun 2022 68.25 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has a healthy Interest coverage ratio of 18.5175449628977.
  • Company’s PEG ratio is 0.338354275569986.
  • The company has an efficient Cash Conversion Cycle of 1.3595123044832 days.
  • The company has a high promoter holding of 68.25%.

 Limitations

  • The company has shown a poor profit growth of -10.6672299318515% for the Past 3 years.
  • The company has shown a poor revenue growth of 2.93533403183093% for the Past 3 years.
  • Company has a poor ROE of 4.3779675012978% over the past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023
Net Sales 23.57 22.43 28.5 43.28 31.13
Total Expenditure 20.44 19.29 24.29 36.6 25.89
Operating Profit 3.13 3.14 4.22 6.69 5.24
Other Income 1.39 0.66 1.11 1.43 0.98
Interest 0.07 0.23 0.28 0.41 0.38
Depreciation 0.27 0.31 0.38 0.37 0.26
Exceptional Items 0 0 0 0 0
Profit Before Tax 4.17 3.26 4.67 7.34 5.58
Tax 1.16 -0.38 0.74 2.21 1.39
Profit After Tax 3.01 3.65 3.93 5.13 4.19
Adjusted EPS (Rs) 1.93 2.34 2.52 3.29 2.69

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Net Sales 50.46 96.42 60.77 70.02 105.16
Total Expenditure 44.88 80.82 59.6 64.69 94.03
Operating Profit 5.58 15.6 1.17 5.33 11.13
Other Income 3.18 5.78 6.14 4.19 4.56
Interest 0.41 0.65 0.93 0.88 0.8
Depreciation 1.19 1.2 1.15 1.14 0.96
Exceptional Items 0 0 0 0 0
Profit Before Tax 7.16 19.52 5.22 7.51 13.93
Tax 0.96 4.76 0.77 1.35 3.4
Net Profit 6.2 14.77 4.46 6.16 10.53
Adjusted EPS (Rs.) 4.51 9.62 2.89 3.97 6.76

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Equity and Liabilities
Share Capital 13.73 15.36 15.43 15.49 15.58
Total Reserves 117.46 135.73 136.21 147.44 162.45
Borrowings 0 0 0 0 0
Other N/C liabilities -1.55 -0.62 -0.57 -0.89 -1.23
Current liabilities 14.17 20.53 22.08 32.53 53.99
Total Liabilities 143.81 171 173.15 194.57 230.79
Assets
Net Block 7.35 7.82 7.67 6.94 14.18
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 70.25 71.24 70.27 70.1 70.15
Loans & Advances 3.59 27.73 38.66 44 46.6
Other N/C Assets 0.79 0 0.54 1.76 2.14
Current Assets 61.84 64.21 56.02 71.76 97.72
Total Assets 143.81 171 173.15 194.57 230.79
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Profit from operations 7.16 19.52 5.22 7.51 13.93
Adjustment -1.36 -2.81 -4.4 -0.46 0.1
Changes in Assets & Liabilities -7.1 -5.12 8.71 0.09 -6.28
Tax Paid -0.02 -4.18 -2.25 -1.01 -2.54
Operating Cash Flow -1.32 7.42 7.29 6.13 5.21
Investing Cash Flow -2.48 -21.9 -10.08 -5.35 -16.08
Financing Cash Flow 5.51 14.69 1.44 2.27 7.55
Net Cash Flow 1.71 0.2 -1.35 3.05 -3.32

Corporate Actions

Investors Details

PARTICULARS Jun 2022% Sep 2022% Dec 2022% Mar 2023% Jun 2023%
promoters 68.25 68.25 68.25 68.25 68.25
bhavin mukund mehta 19.99 19.99 19.99 19.99 19.99
kilitch company (pharma) ... 42.54 42.54 42.54 42.54 42.54
mukund mehta 5.72 5.72 5.72 5.72 5.72
PARTICULARS Jun 2022% Sep 2022% Dec 2022% Mar 2023% Jun 2023%
investors 31.75 31.75 31.75 31.75 31.75
dipak kanayalal shah 3.05 3.06 3.08 3.08 3.08
investor education and pr... - - 1.50 1.50 1.50
investor education and pr... - 1.50 - - -
iepf 1.50 - - - -

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Kilitch Drugs(India) Stock Price Analysis and Quick Research Report. Is Kilitch Drugs(India) an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Kilitch Drugs(India) and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 5.205 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Kilitch Drugs(India) has a Debt to Equity ratio of 0.1161 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Kilitch Drugs(India) , the EPS growth was 70.0699793586064 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Kilitch Drugs(India) has OPM of 10.5824659232901 % which is a bad sign for profitability.
     
  • ROE: Kilitch Drugs(India) have a poor ROE of 6.23389189088365 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Last Updated on:
Brief about Kilitch Drugs(India)
X